Synonyms: MK-7655 | MK-7655A | MK7655
relebactam is an approved drug (FDA (2019), EMA (2020))
Compound class:
Synthetic organic
Comment: Relebactam is a β-lactamase inhibitor [1].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
Relebactam is currently available for use in the clinic in a combination product which includes imipenem and cilastatin, called Recarbrio®. |
External links ![]() |
For extended ADME data see the following: Drugs.com European Medicines Agency (EMA) |